CJC 1295 no DAC (mod GRF 1-29) 5 mg

Modified GRF (1-29) serves as a peptide analogue derived from growth-hormone-releasing hormone (GHRH). Its development in the 1980s stemmed from the revelation that the initial 29 amino acids of GHRH preserved all characteristics of the complete 44-amino-acid protein. The original protein, GRF (1-29), represents the smallest fragment of GHRH maintaining its entire functionality. Another abbreviated synthetic variation, known as Sermorelin or GRF 1-29, comprises 29 amino acids, whereas Modified GRF (1-29) undergoes further modifications by substituting four amino acids within its chain. These substitutions are aimed at preventing degradation and oxidation during manufacturing, transportation, and within the body, concurrently enhancing its affinity to bind with GHRH receptors.

While GRF exhibited full efficacy, its short half-life (less than 10 minutes) limited its duration of action. Consequently, researchers modified GRF (1-29) to extend its half-life, thus amplifying its therapeutic potential. Occasional references to Modified GRF (1-29) include terms like mod GRF or tetrasubstituted GRF (1-29), emphasizing the distinction from GRF (1-29) due to the alteration of four amino acids. Notably, Modified GRF (1-29) mirrors CJC-1295 without DAC in its composition.